In a patient taking dantrolene, a markedly elevated LDH would prompt which action?

In a patient taking dantrolene, a markedly elevated LDH would prompt which action?

• A. Continue the current treatment plan
• B. Notify the primary health care provider
• C. Ignore the result
• D. Switch to a different medication

Answer: (B)

A markedly elevated LDH in a patient taking dantrolene points to possible muscle injury, such as malignant hyperthermia or rhabdomyolysis. LDH is released from damaged cells, and when muscle tissue is breaking down rapidly, LDH levels rise. In the context of dantrolene, this is especially concerning because malignant hyperthermia is a life-threatening emergency that requires immediate attention. Therefore, the appropriate action is to notify the primary health care provider so they can promptly evaluate the patient, order pertinent tests (like CK, electrolytes, and renal function), and adjust treatment as needed. Continuing the same plan or ignoring the result could allow a dangerous reaction to progress, and changing medications should be guided by a clinician after assessment.

A markedly elevated LDH in a patient taking dantrolene points to possible muscle injury, such as malignant hyperthermia or rhabdomyolysis. LDH is released from damaged cells, and when muscle tissue is breaking down rapidly, LDH levels rise. In the context of dantrolene, this is especially concerning because malignant hyperthermia is a life-threatening emergency that requires immediate attention. Therefore, the appropriate action is to notify the primary health care provider so they can promptly evaluate the patient, order pertinent tests (like CK, electrolytes, and renal function), and adjust treatment as needed. Continuing the same plan or ignoring the result could allow a dangerous reaction to progress, and changing medications should be guided by a clinician after assessment.